PUBLIC COMPANY
saveAMR Bio Ltd
founded 2025 · 5 employees · London, GBupdated 1mo ago
AMR Bio is a UK clinical-phase biotechnology company focused on infection prevention. Its lead asset is XF-73 (exeporfinium chloride), a Phase 3-ready topical antimicrobial nasal gel for preventing post-surgical Staphylococcus aureus infections, including MRSA, acquired from Destiny Pharma in 2025.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
comments(0)
5-min edit window · permanent after that